PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

April 9, 2024

https://www.globenewswire.com/news-release/2024/04/09/2860048/0/en/PainReform-s-Non-Opiate-Topical-Treatment-for-Post-Surgical-Pain-Relief-Outperforms-Leading-Competitor-Under-Various-Testing-Conditions.html

TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq:PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to the industry leader for topical post-surgical pain management products. These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in the development of long-lasting pain management solutions.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.